Project Overview
Access to effective emergency contraception (EC) is critical for reducing unintended pregnancies and improving reproductive health outcomes. Through tfho-RESEARCH, Total Family Health Organisation (TFHO) is conducting this study to generate evidence that will inform the introduction of Ulipristal Acetate (UPA) into the Ghanaian market.
UPA is a highly effective oral emergency contraceptive that can prevent pregnancy for up to 120 hours after unprotected intercourse. Compared with commonly used levonorgestrel (LNG)-based emergency contraceptive pills, UPA offers greater effectiveness, particularly between 72 and 120 hours after unprotected sex, and remains effective across a wider range of body mass indices (BMI). Despite these advantages, UPA has limited availability in Ghana, where the emergency contraception market is largely dominated by LNG-based products.
The study addresses a critical evidence gap by examining potential demand for UPA among women and assessing the factors that may influence pharmacists’ and Over-the-Counter Medicine Sellers (OTCMS) decisions to stock and recommend the product.
Objectives
The study aims to:
- Assess the acceptability of Ulipristal Acetate among women of reproductive age.
- Determine women’s willingness to pay for UPA as an emergency contraceptive option.
- Examine factors influencing pharmacists’ and OTCMS providers’ decisions to stock and recommend UPA.
- Generate evidence to support market introduction, pricing, and distribution strategies for UPA in Ghana.
Methodology
This study uses a quantitative cross-sectional design in the Greater Accra Region.
The research will engage:
- Women aged 18 to 49 years who purchase emergency contraceptive pills.
- Pharmacists, pharmacy dispensing staff, and OTCMS providers who stock or recommend emergency contraceptive products.
Data will be collected using structured questionnaires to explore:
- Emergency contraceptive purchasing behaviours and product preferences.
- Prices paid for emergency contraceptive products.
- Willingness to switch to a new emergency contraceptive option.
- Sources of information influencing contraceptive choices.
- Current stocking and pricing practices among providers.
- Willingness of providers to stock and recommend UPA.
- Perceptions of affordability and market demand for UPA.
The study will apply the Van Westendorp Price Sensitivity Meter to estimate acceptable price ranges and affordability thresholds from both consumer and retailer perspectives.
Expected Contribution
This study will provide the first empirical evidence on the market potential for Ulipristal Acetate in Ghana. Findings will support TFHO’s strategy for introducing UPA, guide engagement with private-sector providers, and inform pricing decisions that promote accessibility and sustainability. Ultimately, the project aims to contribute to expanded contraceptive choice, improved access to effective emergency contraception, and better reproductive health outcomes for women in Ghana.